Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SHR-A2102 with adebrelimab with or without other antitumor therapy in advanced or metastatic esophageal squamous cell carcinoma
CTR20242102Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Hengrui Therapeutics. Started Jul 2024; status: active.
02
Drugs
SHR-A2102
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20242102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242102.